Silver Book

Silver Book Fact

A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is better than the others.

MacLean, Catherine, Sydne Newberry, Margaret Maglione, Maureen McMahon, Veena Ranganath, Marika Suttorp, Walter Mojica, Martha Timmer, Alicia Alexander, Melissa McNamara, Sheetal Desai, Annie Zhou, Susan Chen, Jason Carter, Carlo Tringale, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Annals of Internal Medicine. 2008; 148(3): 186-96. http://www.ncbi.nlm.nih.gov/pubmed/18087050

Reference

Title
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
Publication
Annals of Internal Medicine
Publication Date
2008
Authors
MacLean, Catherine, Sydne Newberry, Margaret Maglione, Maureen McMahon, Veena Ranganath, Marika Suttorp, Walter Mojica, Martha Timmer, Alicia Alexander, Melissa McNamara, Sheetal Desai, Annie Zhou, Susan Chen, Jason Carter, Carlo Tringale, et al.
Volume & Issue
Volume 148, Issue 3
Pages
186-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.